Top 5 Drug Type | Count |
---|---|
Small molecule drug | 14 |
Biosimilar | 2 |
Diagnostic radiopharmaceuticals | 2 |
Colony-stimulating factors | 2 |
Monoclonal antibody | 1 |
Target |
Mechanism IL-23p19 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date20 Mar 2018 |
Target |
Mechanism CYP3A4 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. IN |
First Approval Date01 Jan 2012 |
Target |
Mechanism mAChRs antagonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. IN |
First Approval Date01 Aug 2007 |
Start Date01 Jan 2014 |
Sponsor / Collaborator |
Start Date01 Jan 2014 |
Sponsor / Collaborator |
Start Date11 Jul 2013 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Phenobarbital Sodium ( GABAA receptor ) | Epilepsy, Benign Neonatal More | Approved |
Arterolane maleate/Piperaquine Phosphate ( CYP3A4 ) | Malaria More | Approved |
Technetium(99mTc)Methylenediphosphonate | Osteogenesis Imperfecta More | Approved |
Luliconazole ( fungal CYP51A1 ) | Tinea Pedis More | Approved |
Metformin Hydrochloride ( PRKAB1 ) | Diabetes Mellitus, Type 2 More | Approved |